# SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

> **NCT00070941** · PHASE2,PHASE3 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 29 (actual)

## Conditions studied

- Parkinson's Disease
- Depression

## Interventions

- **DRUG:** SAM-e
- **DRUG:** oral escitalopram
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00070941
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2016-07-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070941, "SAM-e for the Treatment of Depression in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00070941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*